SPRAVATO®: In patients’ words
How do patients describe their experiences of using SPRAVATO®?
Patient who received SPRAVATO®
For more information please see the patient booklets here.
This animation has been created using direct quotes from patients with treatment-resistant depression (TRD)** in the clinical trials for SPRAVATO®. It has been designed for patients to view in combination with the patient support kit, once healthcare professionals have made the conscious decision to prescribe the treatment. Please note that side effects experienced by individual patients may differ from those shown in the animation.
Learn more about what makes SPRAVATO® a breakthrough therapy*[1][2]
Connect with peers who have SPRAVATO® prescribing experience.
Access live and recorded meetings
These videos reflect the experiences, ideas and opinions of those featured within them, not necessarily those of Janssen. As such, all content is solely for explanatory purpose, and does not represent any specific recommendation or guidance.
* Quote is the opinion of a single patient with TRD** which is based on their experience of using SPRAVATO®. Other patients’ views, experiences and outcomes may differ. Not all patients responded to SPRAVATO® treatment in clinical trials: in the short-term Phase 3, double-blind, active-controlled, multicentre TRANSFORM-2 trial for TRD,** 69.3% (n=70/101) of patients achieved a response, and 52.0% (n=52/100) achieved remission with SPRAVATO® + oral antidepressant (AD) at Day 28 (vs. 52.5% (n=53/101) and 31.0% (n=31/100) in the placebo nasal spray + oral AD group respectively). Response defined as ≥50% reduction in MADRS total score from baseline; remission defined as MADRS total score ≤12.[3]
** Defined as patients with Major Depressive Disorder who have not responded to two or more ADs in the current depressive episode.[4]
† Following the approval of the SSRI fluoxetine in 1987, approved treatments have continued to primarily target the monoaminergic system.[5][6] In contrast, SPRAVATO® is an antagonist of the NMDA glutamate receptor.[4]
Abbreviations
AD, antidepressant; MADRS, Montgomery–Åsberg Depression Rating Scale; NMDA, N-methyl-D-aspartate; SSRI, selective serotonin reuptake inhibitor; TRD, treatment-resistant depression.
[Insert local AE reporting text as required]
[Insert link to PI]
[Request information from the Janssen Medical Information team]
[Contact your Janssen Account Manager or Medical Scientific Liaison Manager]
